Streetbeat News

EMMA

Emmaus Life Sciences Incorporation

https://www.emmausmedical.com/

CEO

Yutaka Niihara

Employees

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Open

0.01

Mkt cap

741K

Volume

70K

High

0.01

P/E Ratio

-0.23

52-wk high

0.13

Low

0.01

Div yield

N/A

52-wk low

0.00

Emmaus Life Sciences, Inc. reported improved financial results for the three and nine months ended September 30, 2024. The company is a leader in the treatment of sickle cell disease.

Portfolio Pulse from

November 19, 2024 | 10:15 pm

The article highlights insider buying activity in three penny stocks: WidePoint Corporation, ProMIS Neurosciences, and Emmaus Life Sciences. Insider purchases can indicate confidence in a company's prospects, which may influence investor decisions.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 1:17 pm

Great Elm Group, Earth Science Tech, and Emmaus Life Sciences are under $2 stocks with recent insider buying activity. Great Elm Group saw a purchase by Imperial Capital Group Holdings II, LLC, while Earth Science Tech's CEO and Emmaus Life Sciences' Co-President and COO also made significant purchases. These transactions indicate insider confidence in these companies' prospects despite recent challenges such as losses and the announcement of a stock repurchase program.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 11:56 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.